Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + cyclophosphamide + melphalan + prednisone + vincristine
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug is a combination chemotherapy regimen known as VBMCP, consisting of five agents: carmustine, cyclophosphamide, melphalan, prednisone (or prednisolone), and vincristine. It is primarily used in the treatment of multiple myeloma and has also been studied for primary systemic amyloidosis. The regimen combines several alkylating agents (carmustine, cyclophosphamide, melphalan), a corticosteroid (prednisone/prednisolone), and a vinca alkaloid (vincristine). The mechanism of action involves DNA cross-linking and inhibition of cell division by the alkylating agents; immunosuppression and anti-inflammatory effects by the corticosteroid; and disruption of microtubule formation by vincristine. This multi-agent approach aims to maximize cytotoxicity against malignant plasma cells through different mechanisms[1][3][6].
- Other names
- VBMCPvincristine carmustine melphalan cyclophosphamide prednisone
02
Targets
DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carmustine + cyclophosphamide + melphalan + prednisone + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + cyclophosphamide + melphalan + prednisone + vincristine.